These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1065 related articles for article (PubMed ID: 24824495)

  • 1. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
    Stefani A; Alifano M; Bobbio A; Grigoroiu M; Jouni R; Magdeleinat P; Regnard JF
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):356-63. PubMed ID: 20381815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
    Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
    Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
    J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer?
    Xu YJ; Zheng H; Gao W; Jiang GN; Xie HK; Chen C; Fei K
    Interact Cardiovasc Thorac Surg; 2014 Dec; 19(6):887-93. PubMed ID: 25156899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
    J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
    Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
    J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do tumours located in the left lower lobe have worse outcomes in lymph node-positive non-small cell lung cancer than tumours in other lobes?
    Kudo Y; Saji H; Shimada Y; Nomura M; Usuda J; Kajiwara N; Ohira T; Ikeda N
    Eur J Cardiothorac Surg; 2012 Sep; 42(3):414-9. PubMed ID: 22398463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
    Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
    Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer.
    Nentwich MF; Bohn BA; Uzunoglu FG; Reeh M; Quaas A; Grob TJ; Perez D; Kutup A; Bockhorn M; Izbicki JR; Vashist YK
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):781-7. PubMed ID: 23778087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
    Cohen C; Pop D; Venissac N; Poudenx M; Otto J; Castelnau O; Mouroux J
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):129-134. PubMed ID: 28992652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.